Literature DB >> 29611049

Pembrolizumab for primary malignant melanoma of the central nervous system.

Chakib El Habnouni1, Claire Bléchet2, Guido Bens3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29611049     DOI: 10.1007/s11060-018-2848-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

Review 1.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Authors:  David C Whiteman; William J Pavan; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2011-08-16       Impact factor: 4.693

2.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

3.  The use of pembrolizumab for the treatment of metastatic uveal melanoma.

Authors:  Lisa A Kottschade; Robert R McWilliams; Svetomir N Markovic; Matthew S Block; Jose Villasboas Bisneto; Anthony Q Pham; Brandt L Esplin; Roxana S Dronca
Journal:  Melanoma Res       Date:  2016-06       Impact factor: 3.599

  3 in total
  1 in total

1.  Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report.

Authors:  Ana Misir Krpan; Zoran Rakusic; Davorin Herceg
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.